Idexx Laboratories Inc. (IDXX) financial statements: income statement, balance sheet and cash flow

Idexx Laboratories Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Idexx Laboratories Inc. reported revenue of $4.3B (+10.4% year on year) and net income of $1.1B (+19.3% year on year).

Income statement

Idexx Laboratories Inc. income statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Total revenue	$4.3B	$3.9B	$3.7B	$3.4B
Total cost of revenue	$1.6B	$1.5B	$1.5B	$1.4B
Gross profit	$2.7B	$2.4B	$2.2B	$2.0B
Sales and marketing	$643.5M	$588.5M	$566.1M	$524.5M
General and administrative	$404.8M	$442.3M	$335.8M	$326.2M
Research and development	$251.2M	$219.8M	$191.0M	$254.8M
Total operating expenses	$1.3B	$1.3B	—	—
Income from operations	$1.4B	$1.1B	$1.1B	$898.8M
Interest expense	($38.9M)	($31.2M)	($41.6M)	($39.9M)
Interest income	$3.0M	$12.7M	$5.6M	$1.1M
Income before provision for income taxes	$1.3B	$1.1B	$1.1B	$860.0M
Provision for income taxes	$264.7M	$222.0M	$216.1M	$180.9M
Net income	$1.1B	$887.9M	$845.0M	$679.1M
Basic (in USD per share)	$13.17	$10.77	$10.17	$8.12
Diluted (in USD per share)	$13.08	$10.67	$10.06	$8.03
Basic (in shares)	80.4M	82.5M	83.1M	83.6M
Diluted (in shares)	81.0M	83.2M	84.0M	84.6M

Idexx Laboratories Inc. income statement, quarters

Line item	Jun 30, 2026 · Q2	Mar 31, 2026 · Q1	Sep 30, 2025 · Q3	Jun 30, 2025 · Q2
Total revenue	$1.2B	$1.1B	$1.1B	$1.1B
Cost of revenue from reportable segments	$437.5M	$418.1M	$421.9M	$414.7M
Gross profit	$779.1M	$722.7M	$683.4M	$694.7M
Sales and marketing	$171.3M	$175.3M	$159.2M	$161.1M
General and administrative	$116.8M	$119.1M	$105.9M	$98.7M
Research and development	$65.4M	$65.8M	$63.4M	$61.9M
Total operating expenses	$353.5M	$360.2M	$328.5M	$321.7M
Income from operations	$425.6M	$362.6M	$354.8M	$373.0M
Interest expense	($10.2M)	($7.7M)	($10.7M)	($11.3M)
Interest income	$606.0K	$597.0K	$580.0K	$627.0K
Gain (loss) on equity investment	$1.2M	—	—	—
Income before provision for income taxes	$417.2M	$355.4M	$344.8M	$362.4M
Provision for income taxes	$78.8M	$77.0M	$70.2M	$68.4M
Net income	$338.4M	$278.4M	$274.6M	$294.0M
Basic (in USD per share)	$4.29	$3.50	$3.43	$3.66
Diluted (in USD per share)	$4.27	$3.47	$3.40	$3.63
Basic (in shares)	79.0M	79.6M	80.1M	80.4M
Diluted (in shares)	79.3M	80.2M	80.7M	81.0M

Balance sheet

Idexx Laboratories Inc. balance sheet, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Cash and cash equivalents	$180.1M	$288.3M	$453.9M	$112.5M
Accounts receivable, net of allowance of $11,304 in 2025 and $12,585 in 2024	$552.4M	$473.6M	$457.4M	$400.6M
Inventories	$377.8M	$381.9M	$380.3M	$367.8M
Other current assets	$303.6M	$256.2M	$203.6M	$220.5M
Total current assets	$1.4B	$1.4B	$1.5B	$1.1B
Property and equipment, net	$747.4M	$713.1M	$702.2M	$649.5M
Operating lease right-of-use assets	$123.2M	$116.1M	$115.5M	$118.6M
Goodwill	$414.0M	$405.1M	$366.0M	$361.8M
Intangible assets, net	$109.8M	$111.7M	$84.5M	$97.7M
Other long-term assets	$542.5M	$547.5M	$496.5M	$417.7M
Total long-term assets	$1.9B	$1.9B	$1.8B	$1.6B
TOTAL ASSETS	$3.4B	$3.3B	$3.3B	$2.7B
Accounts payable	$110.4M	$114.2M	$110.6M	$110.2M
Accrued liabilities	$530.1M	$502.1M	$478.7M	$433.7M
Credit Facility	$398.0M	$250.0M	$250.0M	$579.0M
Current portion of long-term debt	$75.0M	$167.8M	$75.0M	$75.0M
Current portion of deferred revenue	$35.3M	$33.8M	$37.2M	$37.9M
Total current liabilities	$1.1B	$1.1B	$951.5M	$1.2B
Deferred income tax liabilities	$31.9M	$11.3M	$7.2M	$8.2M
Long-term debt, net of current portion	$374.8M	$449.8M	$622.9M	$694.4M
Long-term deferred revenue, net of current portion	$32.2M	$26.9M	$28.5M	$30.9M
Long-term operating lease liabilities, net of current portion	$101.2M	$97.8M	$99.7M	$101.2M
Other long-term liabilities	$56.5M	$44.3M	$65.5M	$67.6M
Total long-term liabilities	$596.6M	$630.2M	$823.8M	$902.2M
Total liabilities	$1.7B	$1.7B	$1.8B	$2.1B
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 108,369 shares in 2025 and 107,836 shares in 2024; Outstanding: 79,712 shares in 2025 and 81,604 shares in 2024	10.8M	10.8M	10.8M	10.7M
Additional paid-in capital	$1.8B	$1.7B	$1.6B	$1.5B
Deferred stock units: Outstanding: 59 units in 2025 and 60 units in 2024	$6.1M	$5.9M	$5.5M	$5.2M
Retained earnings	$6.4B	$5.3B	$4.4B	$3.6B
Accumulated other comprehensive loss	($68.8M)	($93.6M)	($71.2M)	($77.8M)
Treasury stock, at cost: 28,657 shares in 2025 and 26,232 shares in 2024	-6.6B	-5.3B	-4.5B	-4.4B
Total IDEXX Laboratories, Inc. stockholders’ equity	$1.6B	$1.6B	$1.5B	$608.7M
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$3.4B	$3.3B	$3.3B	$2.7B

Idexx Laboratories Inc. balance sheet, quarters

Line item	Jun 30, 2026	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025
Cash and cash equivalents	$196.9M	$200.5M	$208.2M	$164.6M
Accounts receivable, net	$627.1M	$603.5M	$566.9M	$560.6M
Inventories	$391.6M	$382.4M	$391.6M	$392.6M
Other current assets	$293.9M	$267.6M	$310.4M	$244.6M
Total current assets	$1.5B	$1.5B	$1.5B	$1.4B
Property and equipment, net	$733.2M	$740.4M	$739.4M	$739.7M
Operating lease right-of-use assets	$122.8M	$121.4M	$128.2M	$129.8M
Goodwill	$410.9M	$412.1M	$413.7M	$414.5M
Intangible assets, net	$98.2M	$104.8M	$114.8M	$103.7M
Other long-term assets	$567.7M	$552.8M	$513.6M	$580.8M
Total long-term assets	$1.9B	$1.9B	$1.9B	$2.0B
TOTAL ASSETS	$3.4B	$3.4B	$3.4B	$3.3B
Accounts payable	$129.1M	$130.0M	$122.3M	$116.6M
Accrued liabilities	$453.2M	$453.6M	$488.9M	$417.0M
Credit Facility	$519.0M	$530.0M	$455.0M	$579.0M
Current portion of long-term debt	$150.0M	$150.0M	$150.0M	$75.0M
Current portion of deferred revenue	$36.4M	$36.3M	$35.7M	$36.3M
Total current liabilities	$1.3B	$1.3B	$1.3B	$1.2B
Deferred income tax liabilities	$52.6M	$44.6M	$3.7M	$2.1M
Long-term debt, net of current portion	$299.9M	$299.9M	$374.8M	$449.8M
Long-term deferred revenue, net of current portion	$32.6M	$32.3M	$31.1M	$31.8M
Long-term operating lease liabilities, net of current portion	$100.5M	$98.7M	$106.5M	$107.6M
Other long-term liabilities	$56.5M	$54.0M	$57.6M	$56.8M
Total long-term liabilities	$542.1M	$529.5M	$573.7M	$648.1M
Total liabilities	$1.8B	$1.8B	$1.8B	$1.9B
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 108,717 shares in 2026 and 108,369 shares in 2025; Outstanding: 78,874 shares in 2026 and 79,712 shares in 2025	10.9M	10.8M	10.8M	10.8M
Additional paid-in capital	$1.9B	$1.9B	$1.8B	$1.7B
Deferred stock units: Outstanding: 26 units in 2026 and 59 units in 2025	$5.9M	$6.2M	$6.2M	$6.2M
Retained earnings	$7.0B	$6.7B	$6.1B	$5.9B
Accumulated other comprehensive loss	($63.5M)	($64.9M)	($73.0M)	($77.0M)
Treasury stock, at cost: 29,843 shares in 2026 and 28,657 shares in 2025	-7.3B	-6.9B	-6.3B	-6.1B
Total stockholders’ equity	$1.6B	$1.6B	$1.6B	$1.5B
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$3.4B	$3.4B	$3.4B	$3.3B

Cash flow statement

Idexx Laboratories Inc. cash flow statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Net income	$1.1B	$887.9M	$845.0M	$679.1M
Depreciation and amortization	$145.2M	$129.9M	$114.9M	$111.9M
Provision for uncollectible accounts	$8.4M	$6.9M	$5.6M	$5.8M
Deferred income taxes	$131.2M	($24.2M)	($48.3M)	($35.1M)
Share-based compensation expense	$60.0M	$60.3M	$59.7M	$49.8M
Other	$5.0M	$1.2M	$520.0K	$2.6M
Accounts receivable	($68.7M)	($28.3M)	($53.9M)	($41.4M)
Inventories	($789.0K)	($28.0M)	($28.7M)	($121.7M)
Accounts payable	($8.6M)	$8.1M	($557.0K)	$3.5M
Deferred revenue	$6.9M	($4.4M)	($3.0M)	($11.0M)
Other assets and liabilities	($156.4M)	($80.7M)	$13.7M	($102.8M)
Net cash provided by operating activities	$1.2B	$929.0M	$906.5M	$543.0M
Purchases of property and equipment	($124.7M)	($120.9M)	($133.6M)	($148.8M)
Acquisitions of intangible assets	($13.6M)	($10.0M)	$0	($10.0M)
Equity investments	($756.0K)	($1.0M)	$0	($25.0M)
Acquisitions of businesses, net of cash acquired	$0	($76.7M)	$0	($11.5M)
Proceeds from net investment hedges	$2.7M	$1.6M	$8.4M	—
Net cash used by investing activities	($136.2M)	($207.1M)	($125.3M)	($195.3M)
Borrowings (payments) on revolving credit facility, net	$148.0M	$0	($329.0M)	$505.5M
Payments of senior notes	($178.4M)	($75.0M)	($75.0M)	($75.0M)
Borrowings on term loan	$250.0M	—	—	—
Payments of term loan	($250.0M)	—	—	—
Debt issuance costs	($3.7M)	$0	$0	($435.0K)
Repurchases of common stock	($1.2B)	($837.0M)	($71.9M)	($819.7M)
Proceeds from exercises of stock options and employee stock purchase plans	93.4M	44.5M	47.0M	35.7M
Payments of acquisition-related contingent consideration and holdbacks	$0	$0	($3.1M)	($6.4M)
Shares withheld for statutory tax withholding payments on restricted stock	-7.2M	-10.5M	-10.0M	-10.6M
Net cash used by financing activities	($1.2B)	($878.1M)	($442.0M)	($370.9M)
Net effect of changes in exchange rates on cash	$11.2M	($9.5M)	$2.1M	($8.6M)
Net increase (decrease) in cash and cash equivalents	($108.2M)	($165.7M)	$341.4M	($31.9M)
Cash and cash equivalents at beginning of period	$288.3M	$453.9M	$112.5M	$144.5M
Cash and cash equivalents at end of period	$180.1M	$288.3M	$453.9M	$112.5M

Idexx Laboratories Inc. cash flow statement, quarters

Line item	Jun 30, 2026 · YTD	Mar 31, 2026 · Q1	Sep 30, 2025 · YTD	Jun 30, 2025 · YTD
Net income	$616.9M	$278.4M	$811.3M	$536.7M
Depreciation and amortization	$78.7M	$37.7M	$106.5M	$69.8M
Impairment charge	$5.0M	$5.0M	$0	$0
Provision for credit losses	$6.3M	$3.9M	$6.0M	$4.4M
Deferred income taxes	$20.4M	$13.9M	$99.7M	$6.4M
Share-based compensation expense	$32.4M	$16.3M	$43.9M	$29.5M
Other	$376.0K	$695.0K	$3.2M	$1.5M
Accounts receivable	($82.8M)	($56.8M)	($82.6M)	($74.9M)
Inventories	($1.8M)	$2.2M	($2.2M)	($4.1M)
Other assets and liabilities	($66.5M)	($46.4M)	($160.9M)	($139.9M)
Accounts payable	$4.5M	$11.2M	($5.0M)	($12.1M)
Net cash provided by operating activities	$613.4M	$266.2M	$826.0M	$423.7M
Purchases of property and equipment	($56.6M)	($32.0M)	($95.2M)	($64.1M)
Acquisition of intangible assets	($3.7M)	($1.8M)	($13.3M)	—
Equity investments	($799.0K)	($799.0K)	($756.0K)	—
Proceeds from net investment hedges	$2.1M	$1.0M	$1.2M	$890.0K
Net cash used by investing activities	($59.0M)	($33.5M)	($108.1M)	($63.2M)
Borrowings (payments) on revolving credit facility, net	$121.0M	$132.0M	$205.0M	$329.0M
Payments of senior notes	$0	—	($103.4M)	($103.4M)
Repurchases of common stock, including excise tax settlements	($697.8M)	($351.0M)	($979.2M)	($739.0M)
Proceeds from exercises of stock options and employee stock purchase plans	51.1M	18.2M	75.5M	24.5M
Shares withheld for statutory tax withholding payments on restricted stock	-10.9M	-10.6M	-7.2M	-7.1M
Net cash used by financing activities	($536.6M)	($211.4M)	($809.3M)	($496.0M)
Net effect of changes in exchange rates on cash	($888.0K)	($816.0K)	$11.2M	$11.8M
Net increase (decrease) in cash and cash equivalents	$16.9M	$20.5M	($80.1M)	($123.7M)
Cash and cash equivalents at beginning of period	$180.1M	$180.1M	$288.3M	$288.3M
Cash and cash equivalents at end of period	$196.9M	$200.5M	$208.2M	$164.6M
Unpaid property and equipment, reflected in accounts payable and accrued liabilities	$9.7M	$8.3M	$6.8M	$8.5M

Idexx Laboratories Inc. score and earnings-call analysis · All covered companies

Figures as reported in SEC filings. General information, not investment advice.